Regeneron shares fell nearly 13% before the bell on Friday after its experimental drug for patients with a type of lung ...

Results released Friday show itepekimab succeeded in one Phase 3 trial but failed in a second, sinking shares of both partner ...

Market Overview: The Global Nasal Polyposis Drugs Market is expanding rapidly, owing to advances in biologic medicines, minimally invasive surgical procedures, and personalized medicine approaches.

Sanofi and Regeneron Pharmaceuticals reported mixed results for two late-stage trials of an experimental respiratory drug they are jointly developing, with one study meeting the primary goal and a ...

Nucala gains new indication; FDA implements stricter guidance for COVID-19 vaccine approval; pruritus reported following discontinuation of long-term antihistamines; antibiotic looks promising for ...

A recent study revealed that up to 2 of 5 smokers in the U.S. live with a disability. According to research published in the ...

Regeneron and Sanofi's COPD drug itepekimab cut exacerbations by 27% in one Phase 3 trial, while the second trial did not ...

With the ongoing measles outbreak in the US, the case tally has reached a surprising number of 1,088, according to the U.S.